Zydus Lifesciences reported a solid year-on-year performance for the third quarter ended December 31, 2025, with strong growth in revenue and steady profitability, supported by higher product sales and controlled operating costs.
Revenue from operations for Q3 FY26 came in at ₹6,864.5 crore, marking a 30.3% YoY increase compared with ₹5,269.1 crore recorded in Q3 FY25. The growth was primarily driven by higher sales volumes across key therapeutic segments and improved market traction in domestic and international markets.
Total income for the quarter stood at ₹6,975.9 crore, up 30.9% YoY from ₹5,326.6 crore in the corresponding quarter last year, reflecting both operating growth and stable other income contributions.
On the cost front, total expenses rose to ₹5,537.6 crore, compared with ₹4,142.5 crore in Q3 FY25, an increase of 33.7% YoY. The rise in expenses was mainly due to higher raw material consumption, employee benefit costs, and other operational expenses linked to expanded business activity.
Despite elevated costs, profit before tax and share of profit from joint ventures improved to ₹1,353.4 crore, registering a 14.3% YoY growth over ₹1,184.1 crore reported in the same quarter last year, indicating sustained operating strength.
Net profit from continuing operations for the December quarter stood at ₹1,042.1 crore, marginally higher by 1.8% YoY compared with ₹1,023.8 crore in Q3 FY25. Profit growth remained modest as higher operating expenses and tax outgo partially offset revenue gains.